Bristol Myers Squibb is set to showcase new clinical and real-world findings on Camzyos (mavacamten) for obstructive and non-obstructive hypertrophic cardiomyopathy at the ESC Congress 2025. The presentations include data from the global COLLIGO-HCM study, a pooled Phase 3 monotherapy analysis, and highlights from the largest trial to date in non-obstructive HCM.